BrainQ

BrainQ develops a platform for precision neurology therapies to treat the impaired brain using a BCI-based approach. The company was founded in 2016 and is headquartered in Jerusalem, Yerushalayim, Israel.

BrainQ is an Israeli firm developing a wearable device for AI-based electromagnetic field therapy designated for stroke patients. The device is still in its development stage and is expected to feed patient data to BrainQ’s cloud service to produce treatment patterns. The device can be operated using BrainQ’s app and can be controlled by caregivers or through an integration with a telemedicine device for remote monitoring. In early 2021, BrainQ received the FDA Breakthrough Device certification for its investigational stroke therapy device.

A concentration of wealth and a willingness to adopt age-in-place technologies present new opportunities.

Age Tech

BrainQ is a pioneering neurotechnology company dedicated to developing precision neurology therapies to treat impaired brain functions. Based in Israel, the company has created a groundbreaking platform that utilizes Brain-Computer Interface (BCI) technology to stimulate damaged areas of the brain, promoting self-repair and recovery.

Besides Elon Musk’s Neuralink, 10 neurotech startups that want to read your brain — TFN

Company Information, Competitors, News & FAQs

Bridging the gap between the human brain and computer

Brain-computer Interfaces

BrainQ raises $40M to transform stroke patient rehabilitation with its home therapy device

BrainQ is an Israeli firm developing a wearable device for AI-based electromagnetic field therapy designated for stroke patients. The device is still in its development stage and is expected to feed patient data to BrainQ’s cloud service to produce treatment patterns. The device can be operated using BrainQ’s app and can be controlled by caregivers or through an integration with a telemedicine device for remote monitoring. In early 2021, BrainQ received the FDA Breakthrough Device certification for its investigational stroke therapy device. Key customers and partnershipsBrainQ collaborates with leading healthcare institutions and research organizations to validate and expand its technology. Notable partnerships include <a href="https://www.hackensackmeridianhealth.org/en/news/2023/01/24/hmjfk-johnson-rehabilitation-institute-is-researching-a-breakthrough">Hackensack Meridian Health</a>, <a href="https://kesslerfoundation.org/press-release/kessler-partners-brainq-national-trial-innovative-approach-stroke-rehabilitation">Kessler Foundation</a>, and <a href="https://www.prnewswire.com/news-releases/brooks-rehabilitation-participates-in-national-stroke-recovery-trial-using-breakthrough-technology-301631589.html">Brooks Rehabilitation</a>, which participate in clinical trials to test the efficacy of BrainQ's devices (2022–2023).

Honor provides a platform for elderly persons and their families to find home care providers, and is claimed to be one of the largest on-demand home care networks in the US. The company’s key offerings include Home Care, Family Caregiver Resources, and the Honor Family App and Honor Family Care Network for remote monitoring.In August 2021, Honor announced the acquisition of home care provider Home Instead at an undisclosed value. The merged entity was expected to combine for over USD 2.1 billion home care services revenue.&nbsp; Key customers and partnershipsAs of August 2021, Home Instead had around 90,000 caregivers serving at 1,200 locations across the US and global markets. Home Instead acquired UK-based online platform SuperCarers in June 2020. It connects professional caregivers to elderly people seeking at-home care. Prior to the acquisition, SuperCarers had raised a total of GBP 4.9 million (USD 6.6 million).It also partners with the Organisation for the Review of Care and Health Applications (ORCHA) to provide quality assured apps for psychological wellbeing, physical activity, and mental stimulation.

Honor

Eargo specializes in developing hearing aid and related services. Eargo has four products in its lineup: Link by Eargo, Eargo SE, Eargo Neo HiFi, Eargo 6, and Eargo 7. The company’s products are unique due to its design meant to keep the device invisible when plugged in.The products are priced between USD 749 (Link by Eargo) and USD 2,490 (Eargo 7). The Eargo Neo HiFi comes alongside an app and offers connected smart features such as audio personalization and control. The app allows the user to control the audio to suit their surroundings, customize settings, and contact Eargo's licensed hearing professionals for consultation and support.In October 2020, Eargo was listed as a public company and then acquired by Patient Square Capital In October 2023. Via the acquisition, Patient Square Capital acquired all outstanding shares of Eargo—that were not owned by Patient Square—at USD 2.55 per share. Key customers and partnershipsThe company utilizes a business-to-consumer (B2C) online retail strategy compared to traditional business-to-business (B2B) model deployed by other manufacturers who sell their products through clinics. The strategy has proven beneficial through the Covid-19 pandemic as consumer footfall for brick-and-mortar clinics have declined.

Eargo

K4Connect provides technology solutions to residents and staff members in senior living communities through its K4Community platform. The company was co-founded by Scott Moody who sold his fingerprint sensor technology company AuthenTec to Apple for USD 356 million in 2012, which then became the basis for Touch ID.The platform's offerings include digital voice and video communication, and community updates for residents. It also provides smart home automation through the provisioning of plug and play Alexa devices for residents and supports smart thermostats, smart lights, motion sensors, and sleep tracking devices. In addition, community staff members have access to tools for resident surveys, resident and family management, and communications. During the Covid-19 pandemic, the platform also established an expanded video chat service to facilitate resident-to-resident communication, staff requests, yoga classes, and dining room bookings. Further, in March 2020, it partnered with software communications firm Bandwidth to introduce a hotline for staff and residents as a means of keeping all parties up to date with community information.The platform is built on the company’s patented operating system, FusionOS. The company claims that FusionOS is an advanced multi-modal edge-cloud architecture, the first of its kind in the senior living industry. Residents and staff can access the platform using a smartphone app or pre-provisioned tables in the living communities priced on a per-resident basis.As of July 2020, the platform served over 800 independent and assisted living senior living communities across the US. The platform serves over 29,000 users at more than 125 senior living communities across 27 customers as of February 2020, more than doubling its users from 2018, which it expects to repeat in 2020. The company has established channel partnerships with Allbridge (a data, video and voice solution provider for senior living) in July 2020, and Eskaton (a senior services provider) and White Horse Village (a continuing care retirement community) in May 2019. It collaborated with GlobalLogic (a digital product engineering company) in July 2020 to expedite the development schedule of its K4Community Plus app in response to Covid-19.

K4Connect

CarePredict was founded by Former IBM consultant and tech veteran, Satish Movva, and produces Tempo smart wearables for the elderly community. Using machine learning (ML), the company claims the app can reduce the chance of a fall, and predict urinary tract infections (UTIs) and depression ahead of a clinical diagnosis. The device aims to assist caregivers in taking preventive action by detecting activities and behaviors which are precursors to health declines. The data from the device can also be shared with family members.The company generates revenue from device sales and subscriptions. Independent research conducted in September 2020 indicated that facilities using CarePredict’s wearables reported 40% fewer hospitalizations 69%, lower fall rates, 67% increased length of stay, and a 37% improved staff response rate than facilities that did not use CarePredict.The company expanded its operations in 2018 through its acquisition of WiseWare, a company selling activity-tracking jewelry for older users. In April 2020, it launched the PinPoint contact-tracing tools to mitigate the spread of Covid-19.Key customers and partnershipsIn February 2021, the company announced its partnership with Middle Alabama Area Agency on Aging (M4A). M4A is the agency behind the “Providing Alzheimer's N' Dementia Assistance” (PANDA) project. The company will be the first tech platform to be part of the project and will provide caregivers assistance in remote monitoring and preventive care using its smart wearables.

CarePredict

Eversound develops wireless headphone systems to enhance the level of engagement and social interaction for the elderly living in assisted living or memory care centres. The platform provides a library of programmed content on a variety of topics. The headphone system can be used to communicate with caregivers, during group events, family visits, and for music therapy. The headphones are equipped with a wireless transmitter and volume controls. It connects to external audio sources such as community A/V systems, televisions, and audio devices.The product was unveiled in May 2016. In a subsequent six month study conducted by LCB Senior Living community, group events leveraging the Eversound system resulted in an 18% reduction of residents falling asleep and a 28% increase in engagement during group events. In December 2016, the company expanded to 18 states across the US.In March 2020, as a part of its Covid-19 response, the company launched a live streamed, interactive content service to help seniors combat isolation. Further, as in-person visits at assisted living communities were interrupted due to the Covid-19 pandemic, the use of Eversound’s visitation package proved to be crucial for socially distanced in-person visits. Key customers and partnershipsAs of December 2020, the company’s product is being used in more than 700 senior living communities across the US. Its clients include senior living communities such as Brightview, Commonwealth, and Oakmont. In addition, Eversound has established partnerships with senior living communities (such as The Arbor Company, Bridges by EPOCH, Christian Horizons, and Kisco) to roll out its devices for family visitations, and programmable and live streamed content.

Eversound

Tech-enabled equipment or companionship services that help elderly people function independently.

Platforms that match seniors with home care providers as well as app-based products to facilitate communication between senior families and caregivers

Tech-enabled products used to diagnose, prevent, and treat conditions common among seniors.

Remote monitoring, medical diagnosis, communication, and coordination between caregivers and families of the elderly.

Platforms that help seniors interact socially and communicate with others.

Platforms that help seniors and their families plan and make arrangements to settle the senior’s estates and affairs in the event of death.

Companies that use GenAI as a core part of their product offering for Age Tech

Offers digital platforms that support the wellness of the senior population

Age Tech providers incorporate GenAI to enhance both seniors’ and caregivers’ experiences

Many devices that help seniors operate independently and receive remote treatment use IoT

Some companies use VR to help treat seniors with conditions such as isolation and dementia

BrainQ is a pioneering neurotechnology company dedicated to developing precision neurology therapies to treat impaired brain functions. Based in Israel, the company has created a groundbreaking platform that utilizes Brain-Computer Interface (BCI) technology to stimulate damaged areas of the brain, promoting self-repair and recovery.
BrainQ's innovative approach involves a device that delivers targeted stimulation to the affected regions of the brain. This stimulation aims to activate neuroplasticity, the brain's innate ability to reorganize and form new neural connections, ultimately facilitating rehabilitation and functional improvement.
The company's cutting-edge technology has shown promising results in clinical trials involving ischemic stroke survivors. By harnessing the power of BCI and leveraging the brain's natural healing mechanisms, BrainQ aims to revolutionize the treatment of neurological conditions and improve the quality of life for patients suffering from brain impairments.

Neuralink is a neurotechnology company founded by Elon Musk with the goal of developing brain-computer interfaces (BCIs). The company's flagship product is the N1 Implant, a coin-sized device that is surgically implanted in the brain. The implant contains 1,024 electrodes distributed across 64 ultra-thin threads that can monitor neural activity and electrically stimulate the brain. It wirelessly transmits brain data to external devices, allowing users to control computers or mobile devices directly with their thoughts.
Neuralink's initial focus is on providing digital freedom for people with quadriplegia by enabling them to interact with technology using neural signals. The N1 Implant will be placed in the motor cortex region of the brain that controls movement intention. As of March 2024, Neuralink has implanted its device in at least one human participant, allowing them to control a computer mouse cursor and play video games purely by thinking.
The implant surgery is performed using a custom robotic system developed by Neuralink. This surgical robot automatically inserts the electrode threads into the desired brain region with high precision. Neuralink claims the robotic implantation process aims to be as minimally invasive as procedures like LASIK eye surgery.
Key customers and partnerships
In November 2023, Neuralink announced its first clinical trial, dubbed the "Prime Study," to evaluate the N1 Implant's safety and functionality in human participants with quadriplegia caused by cervical spinal cord injury or amyotrophic lateral sclerosis (ALS). The study is expected to enroll participants aged 22 and older over a period of six years.
Neuralink has previously collaborated with the University of California, Davis to conduct animal testing of its brain implants on monkeys and other research animals. However, this partnership ended in 2020 amid allegations from an animal rights group regarding the treatment of monkeys during experiments.

Neuralink

Kernel is a neurotechnology company developing non-invasive brain imaging devices. Their flagship product, Kernel Flow, is a wearable headset that uses time-domain functional near-infrared spectroscopy (TD-fNIRS) technology to measure brain activity. Kernel Flow emits near-infrared light and detects changes in blood oxygenation levels in the brain's cortical areas, similar to functional magnetic resonance imaging (fMRI). However, it offers advantages such as portability, affordability, and the ability to measure brain activity in natural environments.
Kernel Flow features 52 modules arranged in four plates that fit on either side of the head. Each module contains two laser sources that generate picosecond pulses of light and six detectors that capture the reflected light. By recording the photon arrival times, the system can measure changes in oxyhemoglobin and deoxyhemoglobin concentrations, providing insights into brain function.
Kernel has conducted studies demonstrating the efficacy of Kernel Flow in various applications, including measuring the psychedelic effects of ketamine, predicting gaming expertise, and assessing cognitive decline. As of January 2022, the company had provided 50 systems to partners for evaluation and launched commercial sales for research teams.

Kernel

Synchron is a neurotechnology company developing an implantable brain-computer interface (BCI) system designed to enable patients with severe paralysis to wirelessly control digital devices through their thoughts and improve functional independence. Their flagship technology, the Stentrode, is an endovascular brain implant that is inserted into the brain's motor cortex via the jugular vein using a minimally invasive endovascular procedure, eliminating the need for open brain surgery.
The Stentrode contains electrodes that detect motor intent signals from the brain, which are wirelessly transmitted to an external device. Using machine learning algorithms and signal processing techniques, these neural signals are then translated into digital commands, allowing the user to control personal devices like computers and smartphones for tasks such as texting, emailing, online shopping, and accessing telehealth services.
In August 2020, Synchron received FDA Breakthrough Device designation, followed by the first Investigational Device Exemption (IDE) in July 2021 for evaluating a permanently implanted BCI. The company has conducted clinical trials in Australia and the US, with the first US implantation occurring in July 2022 at Mount Sinai Health System in New York. As of January 2023, Synchron reported that the Stentrode remained safe and functional in four Australian patients after 12 months, with no serious adverse events or significant signal deterioration.

Synchron

Paradromics is an Austin, Texas-based neurotechnology company developing a high data-rate brain-computer interface (BCI) called the Connexus Direct Data Interface (DDI). The Connexus DDI is designed to collect an unprecedented number of individual neural signals from the brain using a fully implantable device intended for long-term daily use.
The first application of the Connexus DDI is an assistive communication device that translates brain signals into speech and movement in real-time. This revolutionary technology aims to restore the ability to communicate and interact with technology independently for people with conditions like ALS, spinal cord injuries, and stroke that cause severe motor impairment.
In May 2023, Paradromics raised USD 33 million in a Series A funding round led by Prime Movers Lab, with participation from Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity. This investment will enable the company to launch its first-in-human clinical trial for the Connexus DDI.
Additionally, in a significant milestone, the US Food and Drug Administration (FDA) granted the Connexus DDI a Breakthrough Device Designation in May 2023. This designation recognizes the transformative potential of the device and allows for an expedited review process, accelerating its availability to patients.

Paradromics

Cognixion is a leading developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology. Their flagship product, the Cognixion ONE Axon, utilizes electroencephalogram (EEG) technology to provide a non-invasive brain-computer interface. It enables patients with advanced disease progression, such as Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), traumatic injuries, and cerebral palsy, to communicate their responses with their thoughts and mental attention in a wearable, augmented reality headset.
The Cognixion ONE Axon integrates Artificial Intelligence (AI), including GPT large language models, to rapidly support the user's communication intentions and desired outcomes. It provides contextual predictions and suggestions that can be quickly selected and communicated audibly and visually on the front visor as a communication aid. The device aims to become the first FDA-cleared device allowing fully paralyzed or locked-in patients to communicate via a non-invasive brain-computer interface once eye-tracking is no longer usable due to ocular motor decline.
Cognixion's technology combines AI, Augmented Reality, and Assistive Technology, designed to help people with severe motor impairments communicate and interact more effectively and independently with the world around them. Unlike invasive BCI technologies, Cognixion's device can be prescribed and utilized without surgical procedures or significant training, providing a new level of independence and autonomy.
Key customers and partnerships
In May 2023, the Cognixion ONE Axon received US Food and Drug Administration (FDA) Breakthrough Device designation, which will streamline its development and validation process with prioritized feedback from FDA review staff. This designation is awarded to devices that demonstrate the potential to provide more effective treatment for life-threatening or debilitating conditions where no clear alternatives exist.

Cognixion

Non-invasive hardware typically involving wearable devices that can record, monitor and interact with brain activity using methods like electroencephalography (EEG), enabling the control of prosthetic limbs, operating computers, and more

Physical devices implanted in the body, often in the brain, to interface with neural signals such as electrodes or neural implants

Companies that offer software platforms for BCI applications, including cloud platforms that enables neural data storage

Companies that gather, store, analyze, and interpret neural data collected via BCIs in order to generate valuable insights for clinical decision making

Most BCI companies personalize the BCI devices based on the patient's condition and goals

Most BCI companies leverage a digital means of extracting and interpreting neural data, some of which use mobile applications to provide insights

The products/platforms offered by most companies utilize AI/ML in enhancing their offering

BrainQ

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless